Phrixus Pharmaceuticals, Inc.

Phrixus Pharmaceuticals announces Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy

– Phrixus to test Carmeseal-MD™ (P-188 NF) at Cincinnati Children’s Hospital in a single-site, open-label trial against respiratory and cardiac end points –

ANN ARBOR, MI – 14 September 2017 – Phrixus Pharmaceuticals, Inc. (“Phrixus”), a company focused on therapies for Duchenne muscular dystrophy (DMD) and heart failure, today announced agreements with several DMD patient organizations and Cincinnati Children’s Hospital to conduct a first clinical trial of Carmeseal-MD™’s, active pharmaceutical ingredient Poloxamer 188 NF (P-188 NF), for the treatment of DMD in non-ambulatory patients. A number of endpoints will be evaluated including effects of P-188 NF on respiratory endpoints such as forced vital activity and on secondary endpoints related to cardiac and skeletal limb muscle performance.

“Older, non-ambulatory patients with DMD have few treatment options, especially with regard to heart failure and respiratory dysfunction, the two leading causes of death. Therefore, they are in urgent need of additional therapies that can slow or arrest disease progression,” said Dr. John L. Jefferies, Director, Advanced Heart Failure and Cardiomyopathy, Professor, Pediatric Cardiology and Adult Cardiovascular Diseases, The Heart Institute, Professor, Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, who will be the Principal Investigator.

This single-center, open-label Phase 2 study will enroll 8 patients, non-ambulatory boys and young men with early heart failure and respiratory dysfunction on stable regimen of background therapies, including corticosteroids. Patients will be evaluated by cardiac MRI, pulmonary function testing and a number of upper body function tests, including performance of upper limb (PUL). Dosing will be for 52 weeks at 5 mg/Kg of P-188 NF, injected once-a-day subcutaneously, with drug product provided by the National Heart Lung and Blood Institute.

Charley’s Fund and Team Joseph led the funding of this trial, with significant support from Harrison’s Fund, Hope for Gus, JB’s Keys to DMD, Little Hercules, and Michael’s Cause. Phrixus has a history of support from the patient community, with previous funding provided by Coalition Duchenne, Hope for Gus, Michael’s Cause, Ryan’s Quest, and Save Our Sons. “We are excited to join forces with our colleagues in the nonprofit community to support the development of Carmeseal-MD as a treatment for Duchenne,” said Dr. Benjamin Seckler, President of Charley’s Fund. “This pilot study will generate initial data in the Duchenne population for a promising treatment that targets a major unmet need: Duchenne-related cardiac and pulmonary failure. This is an exciting step forward.”

Said Cath Jayasuriya, Founder and Executive Director of Coalition Duchenne: “Coalition Duchenne is pleased to see momentum continue to build for research we first identified and sponsored in 2012 as part of our focus on cardiac and pulmonary issues. We’re grateful for the support the community has provided for the initial stages of development that has led to full funding of this first clinical trial for this promising therapeutic.”

Carmeseal-MD is available outside of the United States through Phrixus’s Expanded Access Program and Ethicor Pharma Ltd., a distributor. For more information, please visit www.ethicorpharma.com or contact enquiries@ethicorpharma.com.

read more

Phrixus Pharmaceuticals announces the first patient with Duchenne muscular dystrophy (DMD) to meet the 15-month mark on Carmeseal-MD™ (Poloxamer 188 NF)

– First patient to be treated with Carmeseal-MD (P-188 NF) outside of the United States through Phrixus’s Expanded Access Program with Ethicor Pharma Ltd. –

ANN ARBOR, MI – 13 September 2017 – Phrixus Pharmaceuticals, Inc. (“Phrixus”), a company focused on therapies for Duchenne muscular dystrophy and heart failure, today announced that the first patient with DMD completed 15-month of treatment with Carmeseal-MD. Treatment was well-tolerated; benefits in these patients included reductions in muscle damage markers such as creatine kinase and cardiac troponin.

“The strong preclinical data, combined with human safety data from over 2,500 patients in un-related indications creates a strong rationale for using P-188 NF, a membrane stabilizer, in DMD, a disease that is characterized by membrane tears due to the absence of functional dystrophin,” said Bruce Markham, Ph.D., Chief Scientific Officer and VP Research of Phrixus. “Providing Carmeseal-MD as an unlicensed special provides an opportunity for specialty physicians outside of the United States to treat patients especially with regard to heart failure and respiratory dysfunction, the two leading causes of death,” added Thomas A. Collet, President & CEO.

Carmeseal-MD is available outside of the United States through Phrixus’s Expanded Access Program and Ethicor Pharma Ltd., a distributor. For more information, please visit www.ethicorpharma.com or contact enquiries@ethicorpharma.com.

read more

Phrixus Pharmaceuticals is developing Carmeseal™ (Poloxamer 188 NF or P-188 NF) for
Duchenne muscular dystrophy and acute decompensated heart failure.

In multiple preclinical models, Carmeseal-MD, also known as Poloxamer-188 NF or P-188 NF, has been shown to seal the tears that characterize cellular membranes in Duchenne muscular dystrophy. Sealing of these tears leads to improved performance and prolonged survival of these cells, which translates into improved function of the heart, the diaphragm and skeletal limb muscle.

Slide1

Carmeseal-MD is under development as a once-a-day subcutaneous injection with initial focus on the treatment of cardiac and respiratory deficits and upper body strength in non-ambulatory boys and young men with DMD.

Video and photos provided courtesy Coalition Duchenne

Share